Cartalax: Following the Claim Back to the Study
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

Cartalax, also spelled Kartalax, is linked in the literature to the tripeptide AED. Evaluating joint-repair claims starts with identifying the actual study material. One primary experiment studied AED in aging rat skin-fibroblast cultures. Researchers measured proteins involved in cell growth, cell death and extracellular-matrix remodeling. A later review discusses cartilage biology and reports broader animal and patient claims. A review summary alone does not verify a controlled trial of a defined product. These sources do not establish that Cartalax rebuilds human joints. The exact formulation, clinical methods, meaningful outcomes and safety evidence need to be checked.

END CARD
Educational draft. Not medical advice. Sources and limitations accompany this film.

SOURCES
[1] Lin’kova et al. (2016): Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro
https://pubmed.ncbi.nlm.nih.gov/27259496/
Primary rat-cell study; indexed abstract reviewed

[2] Myakisheva et al. (2023): Chondrocytes secretory phenotype associated with aging: role in the pathogenesis of osteoarthritis and prospects for peptide bioregulation
https://pubmed.ncbi.nlm.nih.gov/37782637/
Review; English abstract reviewed

EVIDENCE LIMITATIONS
The 2016 cells are rat skin fibroblasts, not human cartilage.
The 2023 review refers to both AED and an animal-tissue polypeptide complex; do not transfer results between them.
Do not state that no human reports exist: the review mentions patients, but this targeted review did not verify a controlled trial and formulation.
Do not substitute the four-amino-acid sequence AEDL for AED.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
Original topic requested by Nina; not attributed to an additional verified Facebook video.